A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

To join this study, you would need to be an adult in the UK (18 years or older) who has recently been diagnosed with multiple myeloma. You would have already completed your initial treatment, which must have included chemotherapy and your own stem cell transplant, and this was roughly 3 to 4 months ago. Importantly, your myeloma should have shown some improvement after these treatments (not gotten worse) but not a complete response, meaning doctors are looking for ways to improve your outcome.

There are also some other important health checks. For example, your general health and how well you can do daily activities would be reviewed by your doctor. You'd also need to have recovered well from any side effects of your previous treatments, except for things like hair loss or mild nerve issues. Your doctors will make sure this study is a good fit for you based on your specific health history and test results.

On the other hand, you wouldn't be able to join if your myeloma has spread to your brain or spinal cord, or if you have a different, non-secretory type of myeloma. Also, if you currently have a serious infection, a problem with your immune system, or if you've already had a different type of stem cell transplant using someone else's cells, or certain other cell therapies, you wouldn't be eligible. Your doctor will go through all the specific rules to ensure the study is safe and appropriate for you.

If you decide to take part in this study, you would be assigned to one of two treatment groups. One group will receive the new cell therapy (ide-cel) along with lenalidomide, and the other group will receive lenalidomide alone. The ide-cel treatment involves collecting some of your immune cells (a process called apheresis), sending them away to be specially prepared, and then giving them back to you through an infusion. Before receiving these cells, you'll have some chemotherapy (fludarabine and cyclophosphamide). The lenalidomide is usually taken as tablets.

You would have regular hospital visits for check-ups, blood tests, and other assessments to monitor your health, how you're responding to treatment, and to check for any side effects. The frequency of these visits might be more intensive at the beginning and then become less frequent over time. The study involves long-term follow-up to track your health and treatment results, which could last for several years. The total time you're involved in the study will depend on your individual response and how long you continue treatment, but there will be ongoing monitoring.